Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
200 participants
OBSERVATIONAL
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Determinants of Warfarin Anticoagulation Effect
NCT00162435
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01119300
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
NCT00634907
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Warfarin treatment group
Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
Blood specimens (whole blood, serum, plasma)
The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood specimens (whole blood, serum, plasma)
The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>18 years of age
* included in the study at the onset of warfarin treatment
* target INR (2-3 for atrial fibrillation, vein thrombosis, pulmonary embolism and 2.5-3.5 for prosthetic heart valves)
* standard indications for warfarin treatment
Exclusion Criteria
* Clinical significant liver affection
* Heart failure, NYHA class III-IV
* Non-compliant - not able to accomplish protocol demands
* Not able to give informed consent
* Long-term antibiotic therapy
* Malabsorption conditions and inflammatory bowel disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oslo
OTHER
Norwegian Medicines Agency
OTHER_GOV
Norway: South-Eastern Norway Regional Health Authority
UNKNOWN
Oslo University Hospital
OTHER
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-001895-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.